Attending the Liver Meeting 2017, the American Association for the Study of Liver Diseases (AASLD)‘s 68th annual meeting, this year were not only researchers and physicians, but also a number of different blog writers. The below are links to some abstracts and blog posts about information presented at this year’s Liver Meeting.
A Few 2017 Liver Meeting Highlights
A Sampling of Blog Posts by Clinical Care Options
A Sampling of Meeting Abstracts Published by Hepatology
- Risk of Hepatitis C transmission from antibody positive-nucleic acid negative liver organs to antibody negative recipients by Khurram Bari, et al. (Abstract 1)
- Improved Short-Term Survival in HCV Patients following Liver Transplantation in the Era of Direct Acting Antiviral Agents by George Cholankeril, et al. (Abstract 4)
- Utilization of Patient-Aligned Care Teams (PACT) clinical pharmacists in the primary care setting to treat and monitor non-cirrhotic patients receiving direct-acting antiviral (DAA) therapy. by Macy Ho, et al. (Abstract 21)
- Treatment of Hepatitis C Virus Leads to Economic Gain Related to Reduction in Cases of Hepatocellular Carcinoma (HCC) in Japan. by Zobair M. Younossi, et al. (Abstract 22)
- C-BREEZE 2: Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent (DAA) Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Genotype (GT)1,2, 3, 4, or 6. by Eric Lawitz, et al. (Abstract 61)
- Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis. by Steven L Flamm, et al. (Abstract 62)
- Do resistance associated substitutions (RAS) or Ribavirin (RBV) use influence treatment success of Sofosbuvir (SOF)/Velpatasvir (VEL) in chronic hepatitis C genotype 3 (GT 3) infection? – Results from the GErman hepatitis C COhort (GECCO). by Stefan Christensen, et al. (Abstract 63)